PDA002

Drug Celgene Corporation
Total Payments
$2.5M
Transactions
131
Doctors
5
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2019 $148,409 38 1
2018 $226,921 37 2
2017 $2.1M 56 5

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $2.5M 131 100.0%

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
CCT-PDA-002-DFU-002 Celgene Corporation $1.6M 5
CCT-PDA-002-DPN-001 Celgene Corporation $469,111 0
CCT-PDA-002-DFU-002 - A phase 2 multicenter, randomized, doubleblind, placebo–controlled, dose range finding study to evaluate the efficacy and safety of intramuscular injection of human placenta-derived cells (pda-002) Celgene Corporation $175,497 2
A phase 2 multicenter, randomized, doubleblind, placebo–controlled, dose range finding study to evaluate the efficacy and safety of intramuscular injection of human placenta-derived cells (pda-002) in subjects who have diabetic foot ulcer with peripheral arterial disease (CCT-PDA-002-DFU-002) Celgene Corporation $144,409 1
CCT-PDA-002-DPN-001 - A Phase 2, Randomized, Double Blind, Placebo Controlled, Dose Range Finding Study to Access the Efficacy and Safety of Intramuscular Injection of Human Placenta- Derived Cells (PDA-002) in Subjects wi Celgene Corporation $48,925 0
CCT-PDA-002-DFU-001 Celgene Corporation $5,248 0
A phase 2, multi-center, randomized, double-blind, placebo-controlled, dose range finding study to evaluate the safety, hemodynamic effects and efficacy of intramuscular injection of human placenta-derived cells (pda-002) in subjects who have diabetic foot ulcer with peripheral arterial disease (CCT-PDA-002-DFU-003) Celgene Corporation $4,000 0
CCT-PDA-002-DFU-002 - A phase 2 multicenter, randomized, doubleblind, placebo controlled, dose range finding study to evaluate the efficacy and safety of intramuscular injection of human placenta-derived cells (pda-002) Celgene Corporation $2,500 0

Top Doctors Receiving Payments for PDA002

Doctor Specialty Location Total Records
Unknown — Roanoke, VA $2.2M 123
, DPM Foot Surgery Belleville, IL $115,107 2
, DPM Foot & Ankle Surgery Los Angeles, CA $72,661 1
, DPM Foot & Ankle Surgery Baltimore, MD $39,876 2
, D.P.M Podiatrist Beverly Hills, CA $27,134 2
Sam Miller — San Antonio, TX $10,250 1

Manufacturing Companies

Product Information

  • Type Drug
  • Total Payments $2.5M
  • Total Doctors 5
  • Transactions 131

About PDA002

PDA002 is a drug associated with $2.5M in payments to 5 healthcare providers, recorded across 131 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.

Payment data is available from 2017 to 2019. In 2019, $148,409 was paid across 38 transactions to 1 doctors.

The most common payment nature for PDA002 is "Unspecified" ($2.5M, 100.0% of total).

PDA002 is associated with 8 research studies, including "CCT-PDA-002-DFU-002" ($1.6M).